[Clinical effects of FUT-187 in reflux esophagitis after gastrectomy].
FUT-187 was orally administered to 38 patients with postgastrectomy reflux esophagitis for 4 weeks. The drug reduced the chief subjective symptoms of reflux esophagitis, such as heartburn, chest pain, precordial pain, and dysphagia for solids in 78.1% of patients. Redness, edema and erosion were also reduced in 53.3% of patients as determined endoscopically. Overall, FUT-187 exhibited an excellent therapeutic effect on the reflux esophagitis which was refractory to conventional treatments.
Toge
T
T
Dept. of Surgical Oncology, Research Institute for Radiation Biology.
Hirai
T
T
Takiyama
W
W
Takashima
N
N
Kawano
K
K
Tamura
Y
Y
Nishimawari
K
K
Iwamori
S
S
Nakanishi
K
K
Kono
H
H
D000284:Administration, Oral; D000368:Aged; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications
D007093:Imidazoles; C058875:sepimostate mesilate